United Laboratories (03933) announced that its wholly-owned subsidiary, Zhuhai United Laboratories Zhongshan Branch, has received approval from the National Medical Products Administration for the consistency evaluation of its Roxithromycin Capsules (specification: 150mg). Roxithromycin Capsules are a second-generation macrolide antibiotic known for their acid resistance, broad antibacterial spectrum, strong tissue penetration, and low incidence of adverse reactions. The product is clinically used to treat infections of the ear, nose, throat, respiratory tract, skin, soft tissues, and genitourinary tract caused by roxithromycin-sensitive pathogens. Currently, the product is listed as a Class B drug in the National Medical Insurance Directory (2025 edition). The company is the first enterprise to pass the consistency evaluation for the roxithromycin capsule formulation. This approval is expected to further strengthen the company's leading position in the anti-infective field. United Laboratories will continue to focus on the research and development of new products, which is anticipated to generate greater returns for the company and its shareholders.